Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Large Patient Population Is Key Driver For Bright Minds' Growth

Epilepsy drugs

BTIG initiated coverage on Bright Minds Biosciences Inc. (NASDAQ:DRUG), a clinical-stage company focused on neurological and psychiatric disorders.

Investment in Bright Minds is based on the expectation that BMB-101 will effectively and precisely treat absence seizures without unacceptable toxicities.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.